Valuation: TTY Biopharm Company Limited

Market Cap 19.89B 610M 545M 499M 455M 853M 57.92B 873M 5.96B 2.4B 30.49B 2.29B 2.24B 96.38B P/E 2024 *
-
P/E 2025 -
Enterprise Value 19.89B 610M 545M 499M 455M 853M 57.92B 873M 5.96B 2.4B 30.49B 2.29B 2.24B 96.38B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
78.69%
Yield 2024 *
-
Yield 2025 -
1 day+0.13%
1 week-0.74%
Current month+0.13%
1 month+1.91%
3 months+7.53%
6 months+7.82%
Current year-1.84%
1 week 79.7
Extreme 79.7
81.1
1 month 78.2
Extreme 78.2
83.8
Current year 71.6
Extreme 71.6
87
1 year 71.6
Extreme 71.6
87
3 years 66.2
Extreme 66.2
87
5 years 66.2
Extreme 66.2
88.5
10 years 54.2
Extreme 54.2
120.5
Manager TitleAgeSince
Chief Executive Officer - 2022-04-17
Director of Finance/CFO - 2015-12-30
Compliance Officer - 2022-04-17
Director TitleAgeSince
Director/Board Member - 1995-07-23
Director/Board Member - 2016-06-23
Director/Board Member 70 2016-06-23
Change 5-day change 1-year change 3-year change Capi.($)
+0.13%-0.74%+0.63%-5.33% 609M
-0.46%+10.80%+63.52%+154.48% 1,263B
-0.97%+2.56%+43.25%+81.96% 658B
-2.05%+1.12%+32.47%+102.74% 521B
-1.54%+1.61%+53.42%+67.10% 391B
-0.78%+2.13%+72.55%+44.25% 369B
-1.69%+2.75%+32.49%+54.35% 307B
-0.72%+8.08%+11.15%+34.09% 290B
-0.12%+5.96%+55.97%+78.44% 252B
-0.21%+9.16%+42.19%+112.41% 212B
Average -0.59%+5.24%+40.76%+72.45% 426.25B
Weighted average by Cap. -0.65%+6.60%+49.14%+97.40%

Financials

2024 2025
Net sales 5.89B 181M 161M 148M 135M 253M 17.16B 259M 1.77B 712M 9.03B 678M 664M 28.56B 6.45B 198M 177M 162M 147M 277M 18.79B 283M 1.93B 780M 9.89B 743M 727M 31.27B
Net income 1.45B 44.48M 39.71M 36.37M 33.13M 62.13M 4.22B 63.6M 435M 175M 2.22B 167M 163M 7.02B 1.56B 47.84M 42.71M 39.12M 35.63M 66.82M 4.54B 68.41M 467M 188M 2.39B 179M 176M 7.55B
Net Debt - -
Projected Income Statement - Annual - TTY Biopharm Company Limited
Logo TTY Biopharm Company Limited
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
26-11-02 NT$80.00 +0.13% 362,534
26-10-30 NT$79.90 -0.62% 807,595
26-10-29 NT$80.40 +0.37% 440,848
26-10-28 NT$80.10 -0.62% 625,548
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - TTY Biopharm Company Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
80.00TWD
Average target price
92.00TWD
Spread / Average Target
+15.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TTY Biopharm Company Limited
  1. Stock Market
  2. Stocks
  3. 4105 Stock